Výsledky vyhledávání - "Alexa Betzig Schrock"

Spectrum and implications of activating BRAF alterations in advanced prostate cancer (aPC)

Autor: Alex Chehrazi-Raffle, Hanna Tukachinsky, Alexa Betzig Schrock, Justin Hwang, Zeynep Busra Zengin, Luis A Meza, Neal Shiv Chawla, Hedyeh Ebrahimi, Ameish Govindarajan, Daniela V. Castro, Adam Rock, Abhishek Tripathi, Tanya B. Dorff, Sumanta Monty Pal, Geoffrey R. Oxnard, Neeraj Agarwal, Emmanuel S. Antonarakis

Publikováno v: Journal of Clinical Oncology. 41:220-220

220 Background: Activating genomic alterations (GA) in BRAF are rare in aPC and their impact on pathogenesis is poorly understood. However, emerging data suggest that these GA may represent clinically actionable targets (Fenor et al, Clin Transl Onco

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::1a2c1f2af309719cabf60e0f61336e62
https://doi.org/10.1200/jco.2023.41.6_suppl.220

Zobrazit plný text záznamu

Genomic alterations associated with resistance to EGFR monoclonal antibodies (mAb) in real-world patients with metastatic colorectal cancer (mCRC)

Autor: Samuel J Klempner, Julia C. F. C. F. Quintanilha, Matthew Emmett, Ryon Graf, Alexa Betzig Schrock, Hanna Tukachinsky, Geoffrey R. Oxnard, Parvathi Myer

Publikováno v: Journal of Clinical Oncology. 41:52-52

52 Background: mCRC patients with RAS and BRAF mutant tumors do not benefit from treatment with EGFR mAb. However, some RAS/BRAF wild-type patients do not benefit from EGFR mAbs. We sought to investigate additional primary and acquired biomarkers of

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::dc7b89eb32a38c8ef8b21f94bf03ed0b
https://doi.org/10.1200/jco.2023.41.4_suppl.52

Zobrazit plný text záznamu

Landscape of homologous recombination reversion mutations in gynecologic malignancies

Publikováno v: Journal of Clinical Oncology. 40:5576-5576

5576 Background: Homologous recombination (HR) reversion mutations (REV) are biomarkers for predicting resistance to platinum and PARP inhibitor therapies. The biologic diversity of REV represents a diagnostic challenge. An automated computational ap

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::4abf971280ddb68941c4d95a0c30bc49
https://doi.org/10.1200/jco.2022.40.16_suppl.5576

Zobrazit plný text záznamu

A real-world (rw) evidence study quantifying the clinical value of multi-gene testing in early-stage lung adenocarcinoma (LUAD)

Autor: Nathan A. Pennell, Liangliang Zhang, Katherine T Lofgren, Bharathi Muthusamy, Emily Castellanos, Karen Schwed, Olivier Humblet, Alexa Betzig Schrock, Geoffrey R. Oxnard

Publikováno v: Journal of Clinical Oncology. 40:8525-8525

8525 Background: Resected early-stage NSCLC has high risk of recurrence, and tyrosine kinase inhibitors (TKIs) and immune checkpoint inhibitors (ICI), each requiring testing for precision biomarkers, have recently been approved in the adjuvant (adj)

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::322ddb03db5f6264edd625dec5359098
https://doi.org/10.1200/jco.2022.40.16_suppl.8525

Zobrazit plný text záznamu

Utility of liquid biopsy (LB)-based comprehensive genomic profiling (CGP) of circulating tumor DNA (ctDNA) in lymphomas and plasma cell neoplasms

Autor: Douglas A Mata, Vignesh Shanmugam, Brennan James Decker, Alexa Betzig Schrock, Hanna Tukachinsky, Erik Abraham Williams, Jeffrey S. Ross, Meagan Montesion, Geoffrey R. Oxnard, Jo-Anne Vergilio, Mina L. Xu, Jamal K. Benhamida

Publikováno v: Journal of Clinical Oncology. 40:e19543-e19543

e19543 Background: LB-based CGP of ctDNA can facilitate the molecular evaluation of lymphoid and plasma cell neoplasms (PCNs), especially when traditional CGP is infeasible due to insufficient tumor in the blood or tissue or when tissue biopsy itself

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::e355c35e276ef86b306412882f131bea
https://doi.org/10.1200/jco.2022.40.16_suppl.e19543

Zobrazit plný text záznamu

Clinical and genomic characteristics of pts with durable benefit from immune checkpoint inhibitors (ICI) in advanced non-small cell lung cancer (aNSCLC)

Autor: Jacob Sands, Liangliang Zhang, Alexa Betzig Schrock, Geoffrey R. Oxnard

Publikováno v: Journal of Clinical Oncology. 40:9048-9048

9048 Background: The 2-year mark has become a new milestone in pts with aNSCLC receiving immunotherapy. In pts who are progression free at that point, a subset experience ongoing disease control even after stopping active treatment. Some pts experien

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::1e96e8d4900967ed20c0453101f81bd6
https://doi.org/10.1200/jco.2022.40.16_suppl.9048

Zobrazit plný text záznamu

CtDNA shed as a tool to select immune checkpoint inhibitors (ICPI) with or without chemotherapy for patients (pts) with advanced non–small cell lung cancer (aNSCLC)

Autor: Benjamin Besse, Russell Madison, Cheryl D. Cho-Phan, Jeremy Snider, Tamara Snow, Filippo Gustavo Dall'Olio, Khaled A. Tolba, Alexa Betzig Schrock, Geoffrey R. Oxnard

Publikováno v: Journal of Clinical Oncology. 40:9045-9045

9045 Background: ICPI are compelling therapies for pts with aNSCLC given the potential for durable benefit and limited toxicity. Even in tumors with biomarkers associated with ICPI response, early progression (eP) can be seen, leading to chemotherapy

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::c7d0dda43b13e5fb61025b4b75fedf57
https://doi.org/10.1200/jco.2022.40.16_suppl.9045

Zobrazit plný text záznamu

Real-world (rw) analysis of quantitative MET copy number (CN) as a biomarker in NSCLC

Autor: David Chun Cheong Tsui, Jessica Kim Lee, Garrett M. Frampton, Khaled Tolba, Geoffrey R. Oxnard, D. Ross Camidge, Alexa Betzig Schrock

Publikováno v: Journal of Clinical Oncology. 40:9123-9123

9123 Background: MET amplification (amp) can be a de novo driver or mechanism of resistance to targeted therapy. We explored the genomic landscape of MET amp NSCLC, including co-driver alterations and amplicon size, and its association with outcomes

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::20f7164de2828103c6618bd18028181d
https://doi.org/10.1200/jco.2022.40.16_suppl.9123

Zobrazit plný text záznamu

Liquid biopsy (LB)-based comprehensive genomic profiling (CGP) of circulating tumor DNA (ctDNA) for the evaluation of patients with myeloid neoplasms

Autor: Douglas A Mata, Mina L. Xu, Vignesh Shanmugam, Hanna Tukachinsky, Alexa Betzig Schrock, Jeffrey S. Ross, Erik Abraham Williams, Meagan Montesion, Brennan J. Decker, Jo-Anne Vergilio, Geoffrey R. Oxnard, Jamal K. Benhamida

Publikováno v: Journal of Clinical Oncology. 40:e19064-e19064

e19064 Background: LB-based CGP of ctDNA can facilitate the diagnosis, molecular profiling, and monitoring of patients with myeloid neoplasia, particularly when standard CGP is not feasible due to a lack of circulating disease or insufficient tumor i

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::0e0446d644079506cf054231272f2fbe
https://doi.org/10.1200/jco.2022.40.16_suppl.e19064

Zobrazit plný text záznamu

Activating MET kinase domain mutations define a novel molecular subtype of non–small cell lung cancer that is clinically targetable with the MET inhibitor elzovantinib (TPX-0022)

Autor: Federica Pecci, Biagio Ricciuti, Joao Victor Machado Alessi, Adriana Paula de Castro Barrichello, Victor R. Vaz, Giuseppe Lamberti, Jessica Kim Lee, Alexa Betzig Schrock, Vikas K Goel, Zach Zimmerman, Magda Bahcall, Pasi A. Janne, Mark M. Awad

Publikováno v: Journal of Clinical Oncology. 40:9124-9124

9124 Background: In non-small cell lung cancer (NSCLC), MET exon 14 skipping (METex14) mutations and MET amplification can be targeted with MET inhibitors. Here, we describe a novel, actionable molecular subtype of NSCLC characterized by activating M

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::14bb8b51bd3da7bfc134c0d26798eca7
https://doi.org/10.1200/jco.2022.40.16_suppl.9124

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání